High / Low
₹1,860.60 / ₹1,814.20
Key Takeaways
- Sun Pharma was trading 2.34% lower at ₹1,821.30 and close to the lower end of the session range.
- Recent strategic news includes the lerodalcibep licensing agreement and a reported plan to raise about ₹100 billion in domestic bonds to refinance part of the Organon bridge loan.
- By 11:25 AM, cash volume was around 44% of the 20-day average full-session volume, so the fall was not accompanied by unusually heavy cash turnover.
Why Sun Pharma Shares Are Falling 2.3% Today
Sun Pharma slipped to ₹1,821.30 by 11:25 AM, down 2.34% from the previous close of ₹1,865.00. The stock opened at ₹1,860.60, touched a low of ₹1,814.20 and remained close to the lower end of the day’s range, indicating that selling pressure had persisted through the morning.
The company has important recent news, but it is not obviously negative enough to explain the decline on its own. Sun Pharma signed an exclusive licensing agreement for lerodalcibep outside the US and China, expanding its innovative-medicines portfolio. Separately, a roughly ₹100 billion domestic bond issue is being planned to refinance part of the bridge loan used for the Organon acquisition. These are material strategic developments, but the available evidence does not establish either as the direct trigger for the 2.3% fall.
Trading activity also does not look unusually heavy. About 6.10 lakh shares had changed hands by 11:25 AM versus a 20-session average full-day volume of about 13.85 lakh shares, or roughly 44% of the average session. That is meaningful participation, but not the kind of cash-volume pace that by itself points to an aggressive sell-off. At this stage, the decline looks more like sustained price weakness with moderate market participation rather than a volume-led breakdown.
Likely Reason for Today’s Move
Broader pharma/stock weakness rather than one negative company trigger
Sun Pharma is trading near the lower end of the intraday range, while the cash-volume pace remains moderate rather than extreme. Recent company developments are strategically important but do not provide a clear negative explanation for the fall.
- Price near session low: ₹1,821.30 vs ₹1,814.20
- Cash volume by 11:25 AM: ~44% of 20-day average full-session volume
- Cash-market volume pace remains below an average full session
Research the Market — Not Just the Headline
Get data-backed stock, F&O and options research from a SEBI Registered Research Analyst.
Explore WittyTrades Research →
Latest Company Developments
Lerodalcibep Licensing Agreement
28 Sep 2026
Sun Pharma secured rights to manufacture and commercialise lerodalcibep globally outside the US and China, expanding its cardiovascular specialty portfolio.
Domestic Debt Refinancing Plan
29 Sep 2026
A roughly ₹100 billion domestic bond issue is planned to refinance part of the bridge loan used for the Organon acquisition.
US Pricing / Access Development
Sep 2026
Recent US policy and pricing developments remain relevant for Sun Pharma’s specialty portfolio and overseas earnings outlook.
Ownership & Transaction Activity
Promoter Pledge / Encumbrance
Promoter Holding
54.48%
No q/q change
Pledged
1.65%
Of promoter holding
Pledge Change
+0.23 pp
Latest quarter
Pledged Shares
21.52M
Latest available
Recent Ownership / Shareholding
FII/FPI
14.54%
15.94% previous qtr
Mutual Funds
12.84%
11.96% previous qtr
Institutional
36.71%
37.05% previous qtr
MF Schemes
49
47 previous qtr
Mutual Fund Activity
Mutual funds increased their aggregate stake to 12.84% in Jun 2026, with the number of schemes also rising. The largest disclosed fund positions are shown below.
ICICI Prudential Value Fund
89.20M shares
Jun 2026
SBI Nifty 50 ETF
56.69M shares
Jun 2026
Nippon India Large Cap Fund
33.13M shares
Jun 2026
Recent Brokerage Views
Deven Choksey
Accumulate • Target ₹2,218
04 Aug 2026
Cited strength in India formulations, specialty products and innovation.
Motilal Oswal
Buy • Target ₹2,310
01 Aug 2026
Highlighted specialty and branded businesses after the quarterly update.
Third-party brokerage opinions; not WittyTrades recommendations.
Recent Bulk / Block Deal Activity
Sun Pharma has several disclosed block transactions within the trailing 12 months.
24 Jun 2026 • Block
MTBJ / Government Pension Investment Fund accounts
154,424 shares • ₹1,868
18 Nov 2025 • Block
GQG Partners / Reliance Trust
1,446,414 shares • ₹1,763.90
09 Oct 2025 • Block
Goldman Sachs Bank Europe / Goldman Sachs Singapore
148,233 shares • ₹1,631.60
Large transactions provide ownership/liquidity context and are not directional signals on their own.
What to Watch Next
- Whether Sun Pharma stabilises above the ₹1,814 intraday low.
- Whether cash volume accelerates significantly from the current 44%-of-average pace.
- Details of the Organon refinancing and commercial rollout of lerodalcibep.
Looking for Research-Backed Market Opportunities?
Move beyond generic charts with structured research across price action, derivatives, company developments and market activity.
View Research Segments →
Frequently Asked Questions
Why is Sun Pharma share price falling today?
The stock is weak near the session low, but there is no single confirmed negative company trigger. Cash-market participation is meaningful but not unusually heavy, so the fall currently looks more like broader stock/sector weakness than a volume-led breakdown.
How strong is trading participation today?
Participation is moderate rather than exceptional. By 11:25 AM, cash volume was about 44% of the 20-day average full-session volume, so the move had not yet developed into an unusually high-volume sell-off.
What is Sun Pharma’s promoter pledge?
The latest available data shows 1.65% of promoter holdings pledged, up by 0.23 percentage points in the latest quarter.
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is informational and educational, not personalised investment advice or a recommendation. Market data may be delayed; verify current information before acting.
